GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
2.150
-0.040 (-1.83%)
Aug 30, 2024, 4:00 PM EDT - Market closed
GT Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
4.80M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Tonix Pharmaceuticals Holding | 12.46M |
ReShape Lifesciences | 8.05M |
MSP Recovery | 7.51M |
Azitra | 408.20K |
Creative Medical Technology Holdings | 17.00K |
GTBP News
- 2 months ago - GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia - GlobeNewsWire
- 3 months ago - GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 3 months ago - What made GT Biopharma stock more than double on Monday? - Invezz
- 3 months ago - GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results - GlobeNewsWire
- 7 months ago - GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split - GlobeNewsWire
- 9 months ago - Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders - GlobeNewsWire
- 9 months ago - GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia - GlobeNewsWire